Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Down 6.4% in September
Molecular Partners AG (OTCMKTS:MLLCF) Short Interest Down 6.4% in September
Molecular Partners AG (OTCMKTS:MLLCF – Get Rating) saw a large decrease in short interest during the month of September. As of September 15th, there was short interest totalling 126,000 shares, a decrease of 6.4% from the August 31st total of 134,600 shares. Based on an average daily trading volume, of 300 shares, the short-interest ratio is currently 420.0 days.
分子合作伙伴股份公司(OTCMKTS：MLLCF-GET Rating)看到空頭股數在9月份大幅下降。截至9月15日，空頭股數共有12.6萬股，比8月31日的13.46萬股減少了6.4%。以日均成交量300股計算，目前短息比為420.0天。
Wall Street Analysts Forecast Growth
華爾街分析師預測經濟增長
Separately, Credit Suisse Group reduced their price objective on shares of Molecular Partners from CHF 8 to CHF 6 in a research note on Thursday, July 21st.
另外，瑞士信貸集團在7月21日星期四的一份研究報告中將分子合夥公司的股票目標價從8瑞士法郎下調至6瑞士法郎。
Molecular Partners Trading Up 3.5 %
分子合作伙伴交易上漲3.5%
Shares of OTCMKTS:MLLCF opened at $6.29 on Monday. Molecular Partners has a 52-week low of $5.16 and a 52-week high of $32.00. The company has a 50-day simple moving average of $5.72 and a 200 day simple moving average of $9.26.
OTCMKTS：MLLCF的股票週一開盤報6.29美元。Molecal Partners的52周低點為5.16美元，52周高位為32.00美元。該公司的50日簡單移動均線切入位在5.72美元，200日簡單移動均線切入位在9.26美元。
Molecular Partners Company Profile
分子合作伙伴公司簡介
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus.
分子夥伴公司是一家臨牀階段的生物製藥公司，專注於治療性蛋白質的發現、開發和商業化。它的候選產品包括用於治療新血管濕性老年性黃斑變性和糖尿病黃斑水腫的候選DARPin藥物Abempar，該藥物處於第三階段臨牀試驗；以及針對SARS-CoV-2病毒的多特異性DARPin候選藥物MP0420。
See Also
另請參閲
- Get a free copy of the StockNews.com research report on Molecular Partners (MLLCF)
- Archer Daniels Midland: Dividend Hero With 49 Years Of Increases
- Will Fully Autonomous Tractors Make Deere the Tesla of Farming?
- Magna International is Your Auto and EV One-Stop Shop Stock
- EV Battery Maker Freyr Set For Major Global Expansion
- MarketBeat: Week in Review 9/26 – 9/30
- 免費獲取StockNews.com關於分子夥伴的研究報告(MLLCF)
- 阿徹·丹尼爾斯·米德蘭：49年增長的紅利英雄
- 全自動拖拉機會讓迪爾成為農業領域的特斯拉嗎？
- 麥格納國際是您的汽車和電動汽車一站式庫存
- 電動汽車電池製造商Freyr將在全球大舉擴張
- MarketBeat：回顧一週9/26-9/30
Receive News & Ratings for Molecular Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Partners and related companies with MarketBeat.com's FREE daily email newsletter.
每日收到分子合作伙伴的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊，接收分子合作伙伴和相關公司的最新新聞和分析師評級的每日摘要。